Lupin Limited has acquired the specialty product portfolio of Temmler Pharma GmbH & Co. KG. Based in Marburg, Germany, Temmler, which is a part of the Aenova Group, one of the world’s largest pharmaceutical contract manufacturers, has a growing specialty portfolio of 13 products including key central nervous system (CNS) products and specialty products that address rare disease areas like Myasthenia Gravis, Huntington disease as well as fast-growing dermatology products for anti-wart treatment. Since Huntington disease has many symptoms ranging from motoric symptoms to personality changes, both Temmler and Hormosan products can be used to treat the disease.

“We are very pleased to add to our specialty business with this acquisition,” said Ms. Vinita Gupta, chief executive officer, Lupin Limited. “Temmler’s business has a strong strategic fit with Lupin’s Hormosan business in Germany and enables Lupin to bring an enhanced specialty CNS portfolio to the German market.”